|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors显示文摘Factors released by surrounding cells such as cancer-associated mesenchymal stromal cells(CA-MSCs)are involved in tumor progression and chemoresistance.In this study,we characterize the mechanisms by which naYve mesenchymal stromal cells(MSCs)can acquire a CA-MSCs phenotype.Ovarian tumor cells trigger the transformation of MSCs to CA-MSCs by expressing pro-tumoral genes implicated in the chemoresistance of cancer cells,resulting in the secretion of high levels of CXC chemokine receptors 1 and 2(CXCR1/2)ligands such as chemokine(C-X-C motif)ligand 1(CXCL1),CXCL2,and interleukin 8(IL-8).CXCR1/2 ligands can also inhibit the immune response against ovarian tumor cells.Indeed,through their released factors,CA-MSCs promote the differentiation of monocytes towards M2 macrophages,which favors tumor progression.When CXCR1/2 receptors are inhibited,these CA-MSC-activated macrophages lose their M2 properties and acquire an anti-tumoral phenotype.Both ex vivo and in vivo,we used a CXCR1/2 inhibitor to sensitize ovarian tumor cells to carboplatin and circumvent the pro-tumoral effects of CA-MSCs.Since high concentrations of CXCR1/2 ligands in patients*blood are associated with chemoresistance,CXCR1/2 inhibition could be a potential therapeutic strategy to revert carboplatin resistance. | Augustin Le Naour Melissa Prat Benolt Thibault Renaud Mével Léa Lemaitre Helene Leray Marie-Veronique Joubert Kimberley Coulson Muriel Golzio Lise Lefevre Eliane Mery Alejandra Martinez Gwénael Ferron Jean-Pierre Delord Agnès Coste Bettina Couderc | 2020 | Journal of Molecular Cell Biology2020，12，3： | 3 |
| 2 | Neo-adjuvant treatment with erlotinib in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response显示文摘 | Delord J Thomas F Benlyazid A | 2006 | Proc Am Soc Clin Oncol2006，24，： | 1 |
| 3 | Extrathymic T cell differentiation in the human intestine early in life显示文摘 | Howie D Spencer J Delord D | 1998 | J Immunol1998，161，11： | 1 |
| 4 | Carbon cycling in a shallow turbidestuary of southeast Texas: The use of plant pigment biomarkers and wa-ter quality parameters显示文摘 | Bianchi T S Baskaran M Delord J | 1997 | Estuaries1997，20，： | 1 |
| 5 | Implication of tumor microenvironment in chemoresistance:Tumor-Associated stromal cells protect tumor cells from cell death显示文摘 | Castells M Thibault B Delord J | 2012 | Int J Mol Sci2012，13，8： | 1 |
| 6 | Splicing factor and exon profiling across human tissues显示文摘 | DE LA GRANGE P GRATADOU L DELORD M | 2010 | Nucleic Acids Res2010，38，9： | 1 |
| 7 | A phase Ⅰ dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first- line chemotherapy for metastatic breast cancer显示文摘 | Delord JP Dalenc F Pinguet F | 2007 | Oncology2007，72，56： | 1 |
| 8 | HER1/ EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFRinhibitor rash management forum显示文摘 | Perez - Soler R Delord J P Halpem A | 2005 | Oncologist2005，10，5： | 1 |
| 9 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer 显示文摘 | DELORD J P BENNOUNA J ARTRY P | 2007 | Br J Cancer2007，97，3： | 1 |
| 10 | Evolution of the radius of the inverse micelles at bigh diution in the aersol-OT/water/n-decane system显示文摘 | ASSIH T LARCHE F DELORD P | 1982 | J Colloid Interface Sci1982，89，1： | 1 |
| 11 | HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum显示文摘 | Perez-Soler R Delord JP Halpern A | 2005 | Oncologist2005，10，5： | 1 |
| 12 | Population pharmacokinetics of oxaliplatin 显示文摘 | Delord JP Umlil A Guimbaud R | 2003 | Cancer Chemother Pharmacol2003，51，2： | 1 |
| 13 | HER1/EGFR inhibitor-associated rash:future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum显示文摘 | PREZ-SOLER R DELORD J P HALPERN A | 2005 | Oncologist2005，10，5： | 1 |
| 14 | Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer显示文摘 | Delord JP Bennouna J Artru P | 2007 | Br J Cancer2007，97，3： | 1 |
| 15 | Modified(m)7/bevacizumab(B) or modifiedfm) XELOX/ bevazimab with or without eriotinib(E) in first-line metastatic colorectal cancer(MCRC): Results of the feasibility phase of the DREAM-OPTlMOX3 study(GERCOR)显示文摘 | Tournigand C Lledo G Delord] | 2007 | ] Clin Oncol2007，，： | 1 |
| 16 | HER1/EGFRinhibitor-associated rash: futuredi rections for managementand investigation out comes from the HER1/ EGFR inhibitorrash management forum 显示文摘 | Perez-Soler R Delord JP Halpem A | 2005 | Oncologist2005，10，5： | 1 |
| 17 | Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease - free survival in a micrometastasis model of ovarian carcinoma 显示文摘 | Delord JP Allal C Canal M | 2005 | Ann Oncol2005，16，12： | 1 |
| 18 | Selective inhibition of HER2 inhibits AKT signal tranaductiou and prolongs disease-free survival in a micromctastanis model of ovarian carcinoma显示文摘 | Delord JP Alial C Canal M | 2005 | Ann Oncol2005，16，： | 1 |
| 19 | In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR显示文摘 | Diane Balin-Gauthier Jean-Pierre Delord Philippe Rochaix Valérie Mallard Fabienne Thomas Isabelle Hennebelle Roland Bugat Pierre Canal Cuider Allal | 2006 | Cancer Chemotherapy and Pharmacology2006，，6： | 1 |
| 20 | A phase 1b dose-escalation trial of erlotinib,capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients显示文摘 | Delord JP Beale P Van Cutsem E | 2004 | J Clin Oncol ASCO Meeting Abstracts2004，22，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员